Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol in active rheumatoid arthritis with 12-week placebo-controlled phase followed by open-label extension
NL-OMON33758Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Aug 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Certolizumab pegol with Placebo (2 arms). Primary endpoint: ACR20 responder rate at Week 12. Started Aug 2009; status: active, not recruiting.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON33758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33758.